Wird geladen...
Dysphonia after Bevacizumab Rechallenge: A Case Report
Inhibition of vascular endothelial growth factor (VEGF) signaling, an initiator of tumor angiogenesis, inhibits tumor growth and invasion. Bevacizumab, a monoclonal antibody to VEGF, in common use as an adjunct to standard chemotherapy like irinotecan in advanced colorectal cancer, also affects the...
Gespeichert in:
| Veröffentlicht in: | Case Rep Oncol |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
S. Karger AG
2015
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4649738/ https://ncbi.nlm.nih.gov/pubmed/26600773 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000441122 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|